Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations

Ginkgo Bioworks Holdings (NYSE:DNA) Full Year 2024 Results

Key Financial Results

• Revenue: US$227.0m (down 9.7% from FY 2023).
• Net loss: US$547.0m (loss narrowed by 39% from FY 2023).
• US$10.54 loss per share (improved from US$18.37 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ginkgo Bioworks Holdings EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.6%.

Looking ahead, revenue is expected to decline by 2.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the US are expected to grow by 4.4%.

Performance of the American Chemicals industry.

The company's shares are down 28% from a week ago.

Risk Analysis

Be aware that Ginkgo Bioworks Holdings is showing 2 warning signs in our investment analysis and 1 of those shouldn't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.